Remission induction by Raising the dose of Remicade in RA (RRRR) study: Rationale and study protocol for a randomized controlled trial comparing for sustained clinical remission after discontinuation of infliximab in patients with rheumatoid arthritis

Remission induction by Raising the dose of Remicade in RA (RRRR) study: Rationale and study protocol for a randomized controlled trial comparing for sustained clinical remission after discontinuation of infliximab in patients with rheumatoid arthritis

Infliximab, an inhibitor of TNF-α, is one of the most widely used biological disease-modifying antirheumatic drugs. Recent studies indicated that baseline serum TNF-α could be considered as a key indicator for optimal dosing of infliximab for RA treatment to achieve the clinical response and its sus...

Full description

Bibliographic Details
Main Authors: Koji Oba, Nao Horie, Norihiro Sato, Kazuyoshi Saito, Tsutomu Takeuchi, Tsuneyo Mimori, Nobuyuki Miyasaka, Takao Koike, Yoshiya Tanaka
Format: Article
Language:English
Published: Elsevier 2017-12-01
Series:Contemporary Clinical Trials Communications
Subjects:
Rheumatoid arthritis
Infliximab
TNF-α
Randomized controlled trials
Sustained remission
Protocol paper
Online Access:http://www.sciencedirect.com/science/article/pii/S2451865417300819

Internet

http://www.sciencedirect.com/science/article/pii/S2451865417300819

Similar Items